alexa Rituximab and dose dense chemotherapy in primary breast lymphoma.
Oncology

Oncology

OMICS Journal of Radiology

Author(s): Avils A, Castaeda C, Neri N, Cleto S, Nambo MJ

Abstract Share this page

Abstract Treatment of primary breast lymphoma (PBL) remains unsatisfactory. We assess a clinical study to evaluate efficacy and toxicity of a dose dense regimen (CEOP-14) and rituximab in 32 previously untreated female patients with PBL in early stage. There was no difference in complete response rate (87\%), event free-survival (75\%) and overall survival (63\%) compared with historical patients.
This article was published in Haematologica and referenced in OMICS Journal of Radiology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords